This study investigates the use of radiation to treat wet age-related macular degeneration
(AMD). The radiation is delivered using a robotically controlled device that projects
overlapping beams of radiation onto the macula, the part of the eye that is affected by wet
AMD. Participants will be randomized to receive radiation (stereotactic radiotherapy) or
simulated placebo treatment (sham control). They will be followed up regularly for two years,
and then again at the end of three and four years for a safety visit. Participants will also
receive injections of ranibizumab (Lucentis) into their eye if their wet AMD is active.
Ranibizumab is the standard anti-VEGF agent that is used to treat wet AMD. The study aims to
determine if stereotactic radiosurgery can maintain vision and reduce the need for such
regular anti-VEGF injections.